International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 312-316 www.ijprajournal.com ISSN: 2456-4494

Pharmaceutical Care in Type II Diabetes

Lolla Siddhartha[1], Emani Sai Sri Jayanthi[1], Dr P J Praveen Kumar Reddy[2]
1Department of Pharmacy Practice, Pulla Reddy Institute of Pharmacy, Jawaharlal Nehru Technological University, Dundigal, Hyderabad, Telangana, 500043, India
2 Medical Superintendent, Star Hospitals, Financial District, Nanakramguda, Hyderabad, Telangana, 500008, India

Date of Submission: 10-09-2025 Date of Acceptance: 20-09-2025

ABSTRACT
T2DM develops over time and is characterised by insulin resistance and relative insulin insufficiency. It is growing more widespread worldwide, especially in low- and middle-income countries, threatening public health. Type 2 diabetes management requires a multipronged approach, including pharmaceutical treatment. Clinical chemists help ensure medication safety, optimise pharmacotherapy, and improve patient outcomes through customised treatments. Through MTM, patient counselling, lifestyle change assistance, and regular monitoring, chemists help manage type 2 diabetes. Evidence suggests that coordinated pharmacological treatment can improve glycaemic management, reduce hospital admissions, and prevent long-term issues. This includes patient assessment, care plan formulation, implementation, and follow-up. Chemical interventions reduce HbA1c, improve medication adherence, and improve quality of life, according to clinical trials like the RxACTION trial and the Diabetes Ten City Challenge, as well as real-world case studies. Patients' ignorance, a lack of competent chemists, time, and inefficient interprofessional communication hinder pharmaceutical treatment implementation. We need system-wide policies, more chemists on healthcare teams, and more people adopting digital technologies and telepharmacy, especially in impoverished regions, to address these concerns. Pharmaceutical medication is essential for long-term type 2 diabetes management; hence diabetes care models should include it. Chemists can improve therapeutic outcomes, empower patients, and reduce diabetes worldwide by adopting a collaborative, patient-centered approach.

Keywords: Type II Diabetes Mellitus, Pharmaceutical Care, Clinical Pharmacist, Glycemic Control, Medication Adherence, Patient Education, Medication Therapy Management (MTM), Diabetes Outcomes, Telepharmacy.

I. INTRODUCTION

Insulin resistance and relative insulin insufficiency produce long-term hyperglycemia in Type II Diabetes Mellitus (T2DM). Type 2 diabetes (T2DM) is more often connected to lifestyle factors such obesity, poor food, lack of exercise, and inherited predisposition than Type I diabetes, which is autoimmune. According to the International Diabetes Federation, 90% of the world's 537 million diabetics are Type II (Shao et al., 2017). Increasing urbanisation and sedentary lifestyles make the load worse in emerging nations. Over 77 million Indians have diabetes, making it one of the most diabetes-prone nations. Long-term hyperglycemia can cause retinopathy, nephropathy, neuropathy, cardiovascular disease, stroke, and other microvascular and macrovascular complications, making glycaemic control crucial for type 2 diabetes care. Effective blood glucose management reduces morbidity, delays disease onset, and improves quality of life (Nogueira et al., 2020). The disease's complexity, polypharmacy, and patient factors like non-adherence and misinformation make glycaemic goals hard to maintain. Pharmaceutical care, a patient-centered approach where pharmacists manage a patient's drug needs and optimise treatment outcomes, is becoming increasingly important in diabetes management (Wang et al., 2022). Pharmaceutical care focusses on medication adherence, adverse drug reactions, drug-related illnesses, and lifestyle advising. The long-term and intricate nature of type 2 diabetes requires chemists to do more than fill prescriptions. They assist doctors in patient education, therapy monitoring, and individualised treatment program planning. Chemists can cover treatment gaps and improve type 2 diabetes management because to their close interaction with patients and ease of access (Lira-Meriguete et al., 2024).

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 312-316 www.ijprajournal.com ISSN: 2456-4494

Role of the Clinical Pharmacist in Type II Diabetes

Clinical chemists' vital role in interdisciplinary Type II Diabetes Mellitus treatment improves clinical outcomes and patient quality of life. Job duties include medication therapy management (MTM). It involves systematically examining a patient's pharmaceutical profile to ensure safety, enhance therapeutic efficacy, and reduce drug interactions and duplications (Theivasigamani & Palaniappan, 2024). MTM helps chemists decide doses, medication combinations, and treatment plan compliance to help patients take their prescriptions as prescribed. Clinical chemists also educate and coach patients on healthy lifestyles to manage diabetes. They explain how to take medications, why food and exercise are important, how to monitor blood glucose, and how to spot hypo- and hyperglycemia. Individualised education increases patients' agency, which improves self-management and disease control over time (Namiq et al., 2020). Chemists monitor and follow up patients to see if treatment needs to be changed. Pharmacists monitor HbA1c, blood pressure, and lipid profiles and regularly check in with patients to ensure they're following their treatment programs and address any concerns or side effects (Choudhary et al., 2019). Recognising and resolving medication concerns is also important. Side effects, therapeutic duplications, medication interactions, and inappropriate dosages are examples. Clinical chemists quickly fix these issues, ensuring pharmaceutical safety and efficacy. Finally, chemists must collaborate with doctors and other healthcare professionals. Chemists share ideas, clinical data, and patient involvement to generate personalised treatment plans for comprehensive, patient-centered care. This collaborative strategy improves treatment outcomes and builds a strong support system for type 2 diabetes patients (Blahova et al., 2021).

Common Pharmacological Therapies in Type II Diabetes

Pharmacological treatment for Type II Diabetes Mellitus depends on patient features and disease development. Each pharmaceutical class addresses different pathophysiological components of the disease to optimise glycaemic management and minimise side effects (Pizarro et al., 2021). Metformin, a biguanide that lowers liver glucose production and increases insulin sensitivity, is the most commonly prescribed type 2 diabetes medication. Most treatment guidelines recommend it as a first-line medication due to its efficacy, tolerability, weight-free effect, and cardiovascular health benefits. Sulfonylureas like glimepiride and gliclazide, which are insulin secretagogues, increase insulin secretion by pancreatic β-cells. Although they lower blood glucose, they can cause hypoglycemia and weight gain, therefore patients must be carefully selected (Silva et al., 2022). DPP-4 inhibitors like vildagliptin and sitagliptin boost endogenous incretin activity and increase insulin production and reduce glucagon. Since they are well-tolerated and weight-neutral, they are often taken alongside metformin. GLP-1 receptor agonists like liraglutide and dulaglutide mimic incretin hormones to increase insulin production and decrease stomach emptying. These injectable drugs can help with weight loss and cardiovascular health, but they also have gastrointestinal adverse effects. SGLT2 inhibitors dapagliflozin and empagliflozin reduce renal glucose reabsorption and increase urine glucose excretion (Kadhim & Fadil, 2020). These drugs protect the heart and kidneys, making them ideal for comorbid patients. Advanced or uncontrollable cases require insulin treatment. Patient needs and blood glucose profiles influence formulation type (basal, bolus, or premixed). Clinical chemists are essential for medication selection and titration. Patients' renal and hepatic function, hypoglycemia risk, weight, comorbidities, and financial constraints are considered. Chemists assist patients with dose, teach correct administration, handle side effects, and monitor performance. Their expertise ensures personalised, risk-free, and effective type 2 diabetes pharmaceutical treatment, according to Treras-Vergara et al. (2022).

Pharmaceutical Care Process in Diabetes Management

A comprehensive, patient-centered pharmaceutical care procedure for Type II Diabetes Mellitus aims for optimal therapeutic outcomes and self-management. This ongoing and ever-changing process includes assessment, care plan formulation, implementation, and follow-up (Paulo et al., 2022). Clinical chemists start by evaluating their patients' health conditions, medications, test results (including haemoglobin A1c, fasting glucose, lipid profile, and renal function), and other behavioural, nutritional, and social factors. This assessment helps identify drug difficulties, dangers, and adherence barriers. The patient, healthcare team, and chemist establish a tailored care plan based on

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 312-316 www.ijprajournal.com ISSN: 2456-4494

this assessment. This strategy details blood sugar, blood pressure, and cholesterol goals. To address issues, medication regimes are simplified, drug therapy is started or modified, and lifestyle education is provided (Obeid & Hamasaeed, 2023). In this stage, the chemist counsels the patient on medication use, meal changes, exercise, and blood glucose self-monitoring. Work with the patient to set realistic health objectives to motivate and hold them accountable. Finally, the chemist evaluates and follows up with the patient (da Costa, 2019). Check glucose readings, watch for side effects, make sure medicine is taken as prescribed, and adjust the treatment plan if necessary. Ongoing dialogue speeds therapies and boosts patient engagement. Chemists execute this pharmaceutical care technique meticulously to improve type 2 diabetes patients' clinical outcomes and quality of life. This makes diabetes management proactive, customised, and evidence-based.

Patient Counseling and Education

Type 2 diabetic mellitus (T2DM) medication relies on patient education and counselling. Patient education improves treatment outcomes and reduces long-term issues (Abrahamsen et al., 2020). Counselling must teach blood glucose monitoring. Patients must learn how to use glucometers, interpret findings, and spot trends that may indicate therapy changes. Chemists educate patients on monitoring frequency based on treatment regimen and clinical status to encourage prompt decision-making and self-management. Diabetic self-management involves diet and exercise changes. Chemists can advise on healthy eating, portion control, carb counting, and the glycaemic index. Physical activity that matches the patient's age, health, and aptitude is also encouraged. Patient education regarding how food and exercise affect blood sugar levels can boost motivation and adherence (Shao et al., 2017). Another important issue is medication adherence. Non-adherence often causes glycaemic problems. Pharmaceutical experts counsel patients to take their prescriptions as prescribed, discuss their intended use, side effects, and strategies to improve adherence, such as pill organisers or reminders (Nogueira et al., 2020). Patients learn the symptoms of hypoglycemia (sweating, shakiness, dizziness, and disorientation) and hyperglycemia (increased thirst, frequent urination, and weariness). Chemists advise patients on how to handle low blood sugar and recurrent hyperglycemia. Finally, scientists stress the importance of routine testing for diabetes early detection. Annual eye exams, foot exams for neuropathy or ulcers, and renal function tests for nephropathy are routinely monitored. Test quickly to avoid lasting damage and maintain health (Wang et al., 2022). When chemists counsel and educate patients, they can better manage their health, experience fewer side effects, and live a better life.

Impact of Pharmaceutical Care on Clinical Outcomes

T2DM patients' clinical results are considerably and quantifiably changed by pharmacological therapy. Diabetes management is completer and more organised when chemists are involved, according to research. This significantly improves many health indices (Lira-Meriguete et al., 2024). In particular, lower HbA1c readings indicate better glycaemic management. Clinical evidence shows that pharmacist-led medication reviews, patient counselling, and personalised care plans can lower HbA1c and bring glucose levels closer to goal. Therefore, diabetes issues are less likely. Pharmaceutical therapy reduces hospitalisations and complications. Patients who know the symptoms of infections, hypoglycemia, and hyperglycaemia can avoid hospitalisations (Theivasigamani & Palaniappan, 2024). Chemists can monitor their therapy. Regular monitoring and prevention can lessen long-term effects such retinopathy, nephropathy, and cardiovascular disease. Another benefit is better medication adherence. Many type 2 diabetics struggle with difficult regimens, side effects, and drug comprehension. Pharmacy technicians provide personalised counselling, streamline drug regimens, and emphasise consistency to help patients overcome these challenges (Namiq et al., 2020). Adherence improves glycaemic control, treatment failure, and healthcare costs. Finally, pharmaceutical care improves life quality. Diabetes management programs that educate, empower, and assist people reduce concern, symptoms, and doubt in one's ability to live normally. By integrating behavioural, medical, and lifestyle guidance, pharmacists promote long-term health and wellness, according to Choudhary et al. (2019). Pharmaceutical treatment improves Type II Diabetes patients' health, reduces hazards, and boosts clinical efficacy.

Barriers to Effective Pharmaceutical Care

Although pharmaceutical treatment for Type II Diabetes Mellitus (T2DM) offers many

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 312-316 www.ijprajournal.com ISSN: 2456-4494

benefits, it faces some hurdles that limit its potential. If these challenges are not overcome, chemist-led initiatives may fail and harm patients (Blahova et al., 2021). Patients' ignorance of chemists' duties beyond pharmaceutical dispensing is a problem. How few individuals know that pharmacists may aid with disease management, counselling, and clinical guidance is astonishing. People avoid pharmaceutical services and early care due to misinformation like this.Another issue is the lack of clinical chemists, especially in rural and underserved areas. Urban hospitals and specialised clinics are incorporating chemists into their healthcare teams, but primary care settings sometimes lack the clinical competence to provide full pharmaceutical treatment. This discrepancy inhibits the most benefiting persons from obtaining these services (Pizarro et al., 2021). Limited time and funding prevent effective pharmaceutical care. Retail and hospital pharmacists struggle to counsel, follow up, and tailor care due to high workloads (Silva et al., 2022). Without private consultation areas and technology, pharmacist-patient interactions are lowered. Finally, chemist-doctor miscommunications can disrupt care. Lack of teamwork and information exchange can lead to inconsistent treatment regimens, patient confusion, and wasteful therapy duplication or omission. Lack of cooperation prevents chemists from contributing to pharmaceutical therapy optimisation decisions. Better training, interprofessional collaboration, public awareness, and legislative support for clinical pharmacy services are needed to overcome these challenges (Kadhim & Fadil, 2020). Once these problems are overcome, integrated pharmacological treatment into diabetes care will improve patients' health.

Case Studies and Evidence-Based Practices

Pharmacological therapy for Type II Diabetes Mellitus is growing in evidence from clinical trials, intervention models, and real-world case studies. These cases show how interdisciplinary care teams, including chemists, can improve patient outcomes through treatment. Several major clinical investigations have indicated that pharmacological treatment is effective (Contreras-Vergara et al., 2022). Employers in the US diabetic Ten City Challenge developed chemist-led diabetic treatment programs. The results showed lower HbA1c, LDL cholesterol, and blood pressure, as well as fewer healthcare costs. A 0.9% decline in HbA1c was shown in the Canadian RxACTION trial, showing that pharmacist-led treatments improved glycaemic management compared to standard therapy. Practical case studies and randomised controlled trials help illuminate complicated themes. Clinical pharmacists ran a diabetic care program in an Indian community pharmacy that improved medication adherence, patient knowledge, and glycaemic control over six months. According to Paulo et al. (2022), patients felt more in control of their health, and clinicians appreciated chemists' involvement in therapy optimisation. New evidence-based diabetic care includes digital technologies and telepharmacy. Teleconsultation systems, remote monitoring technology, and mobile health apps allow chemists to provide virtual counselling, prescription reminders, and real-time support. Telepharmacy in remote areas is a good example (Obeid & Hamasaeed, 2023). Studies show that patients who use these services, independent of location, have stronger adherence and more stable blood glucose levels. These case studies and intervention models demonstrate that pharmaceutical care improves diabetes control with evidence-based procedures and cutting-edge digital tools. Pharmacists' growing roles in primary care and telehealth are redefining long-term sickness management and emphasising their systematic role.

II. CONCLUSION

Pharmaceutical therapy has swiftly become an essential aspect of T2DM care due to its many clinical, behavioural, and economic benefits. Patients can expect better glycaemic control, medication adherence, diabetes complications, and quality of life from chemists who provide pharmaceutical therapy management, education, counselling, and close monitoring. Clinical and real-world case studies show that pharmacist-led treatment improves patient satisfaction, hospitalisation rates, and HbA1c levels. Due to rising type 2 diabetes rates worldwide, pharmacy services must be integrated into mainstream healthcare systems. Chemists must be recognised as vital components of the interdisciplinary team providing direct patient care as well as drug distributors. Educational institutions, healthcare facilities, and legislators must work together to train more clinical chemists, fund their professional development, and promote collaborative care models. Pharmaceutical care should focus on personalised, patient-centered treatment to help patients manage their illness sustainably. Chemists connect patients and other healthcare practitioners to improve diabetes care and outcomes. This

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 312-316 www.ijprajournal.com ISSN: 2456-4494

collaborative, integrated strategy makes pharmaceutical treatment vital to improving health outcomes and long-term disease control—the future of diabetes management.

REFERENCE

[1]. Shao, H., Chen, G., Zhu, C., Chen, Y., Liu, Y., He, Y., & Jin, H. (2017). Effect of pharmaceutical care on clinical outcomes of outpatients with type 2 diabetes mellitus. Patient preference and adherence, 897-903.

[2]. Nogueira, M., Otuyama, L. J., Rocha, P. A., & Pinto, V. B. (2020). Pharmaceutical care-based interventions in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials. Einstein (Sao Paulo), 18, eRW4686.

[3]. Wang, W., Geng, L., Sun, C., Li, H., & Wang, J. (2022). Efficacy of pharmaceutical care in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. International journal of clinical practice, 2022(1), 7681404.

[4]. Lira-Meriguete, A. M., Santos, M. P., de Souza Viana, V. C., Gonçalves, N. A. Z., Kitagawa, R. R., Carnielli-Queiroz, L., ... & Gonçalves, R. D. C. R. (2024). Can pharmaceutical care decrease the oxidative stress in type 2 diabetes mellitus?. Biomedicine & Pharmacotherapy, 171, 116178.

[5]. Theivasigamani, K., & Palaniappan, S. (2024). An Overview of Pharmaceutical Care in Type II Diabetes Mellitus Patients: Current Position and Prospects. Current Diabetes Reviews, 20(2), 103-111.

[6]. Namiq, H. S., Obeid, K. A., & Mohammed, D. A. (2020). Role of pharmaceutical care in type 2 diabetic patients in Kirkuk City. Al Mustansiriyah Journal of Pharmaceutical Sciences, 20(4), 169-181.

[7]. Choudhary, K., Mali, M., Bhavsar, K., Pawar, S., Diwan, A., & Barsode, S. (2019). Effect of pharmaceutical care services provided by clinical pharmacists on type-2 diabetes patients. vascular diseases, 5, 7.

[8]. Blahova, J., Martiniakova, M., Babikova, M., Kovacova, V., Mondockova, V., & Omelka, R. (2021). Pharmaceutical drugs and natural therapeutic products for the treatment of type 2 diabetes mellitus. Pharmaceuticals, 14(8), 806.

[9]. Pizarro, Â. M. V. P. D. A., Martins, M. R. O., & Simões, J. A. (2021). Exploring the policies applied to pharmaceutical care practice for type 2 diabetes over the last decade in European community pharmacies. Portuguese Journal of Public Health, 39(2), 103-118.

[10]. Silva, W. L. F. D., Matos, D. M. D., Felicíssimo, J. M., Jardim, A. C. B., Cruz, D. T. D., Cazarim, M. D. S., ... & Silvério, M. S. (2022). Profile of pharmaceutical interventions of a pharmacotherapeutic follow-up model for diabetic patients in a community pharmacy. Brazilian Journal of Pharmaceutical Sciences, 58, e20956.

[11]. Kadhim, K. A., & Fadil, S. M. (2020). Effect the Pharmaceutical care and health education on knowledge and disease control for type 2 diabetes mellitus patients: A sample of Iraqi patients. Al Mustansiriyah Journal of Pharmaceutical Sciences, 20(1), 40-54.

[12]. Contreras-Vergara, A., Sifuentes-Franco, S., Haack, S., Graciano-Machuca, O., Rodriguez-Carrizalez, A. D., López-Contreras, A. K., ... & Huerta-Olvera, S. G. (2022). Impact of pharmaceutical education on medication adherence and its clinical efficacy in patients with type 2 diabetes and systemic arterial hypertension. Patient preference and adherence, 1999-2007.

[13]. Paulo, P. T. C., Medeiros, P. A. D. D., Azevedo, P. R. M. D., Diniz, R. D. S., Egito, E. S. T. D., & Araújo, I. B. D. (2022). Pharmaceutical Care Practice and Consequences on Quality of Life and Satisfaction of Diabetic Patients: A Randomized Clinical Trial. Brazilian Journal of Pharmaceutical Sciences, 58, e19500.

[14]. Obeid, K. A., & Hamasaeed, A. G. (2023). The Impact of Insulin Staging in the Context of Pharmaceutical Care on Patients with Type 2 Diabetes Mellitus. Diabetes, Metabolic Syndrome and Obesity, 71-83.

[15]. da Costa, F. A. (2019). Correction to: The Pharmacist Guide to Implementing Pharmaceutical Care. The Pharmacist Guide to Implementing Pharmaceutical Care, 421, 502.

[16]. Abrahamsen, B., Burghle, A. H., & Rossing, C. (2020). Pharmaceutical care services available in Danish community pharmacies. International Journal of Clinical Pharmacy, 42(2), 315-320.